Palpitations

Milestone Pharmaceuticals Partners with Arrhythmia Alliance on SVT Awareness

Retrieved on: 
수요일, 5월 22, 2024

MONTREAL and CHARLOTTE, N.C., May 22, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced it will partner with Arrhythmia Alliance to raise awareness of supraventricular tachycardia (SVT).

Key Points: 
  • MONTREAL and CHARLOTTE, N.C., May 22, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced it will partner with Arrhythmia Alliance to raise awareness of supraventricular tachycardia (SVT).
  • SVT Awareness Day will be held on Wednesday June 5, 2024, during World Heart Rhythm Week (June 4-10), to raise awareness of SVT, a type of arrhythmia or rapid heart rhythm that leaves people with palpitations (“racing heart rate”), breathlessness, and anxiety.
  • “We are honored to partner with the Arrhythmia Alliance on educational initiatives for SVT Awareness Day.
  • For additional information on SVT, visit SVT Heart to Heart provided by Milestone Pharmaceuticals.

Mario Lemieux Foundation, Highmark Health Announce Major Gift to AHN Cardiovascular Institute, Establishing "The Mario Lemieux Center for Heart Rhythm Care"

Retrieved on: 
금요일, 5월 10, 2024

PITTSBURGH, May 10, 2024 /PRNewswire/ -- Representatives from the Mario Lemieux Foundation and Highmark Health today announced a major collaborative gift to Allegheny Health Network's (AHN) Cardiovascular Institute that will further strengthen the organization's nationally recognized cardiac electrophysiology (EP) program. The joint commitment, totaling $5 million, will formally establish "The Mario Lemieux Center for Heart Rhythm Care" at AHN.

Key Points: 
  • The joint commitment, totaling $5 million, will formally establish "The Mario Lemieux Center for Heart Rhythm Care" at AHN.
  • Lemieux Foundation, Highmark Health Announce Major Gift to AHN, Establish The Mario Lemieux Center for Heart Rhythm Care
    This is the second philanthropic gift to AHN's EP program from the Mario Lemieux Foundation.
  • In 2019, the Foundation created the "Mario Lemieux Innovation and Research Fund" through a $1 million gift, which also was matched by Highmark Health.
  • In 2005, hockey legend Mario Lemieux was diagnosed with atrial fibrillation (AFib), the most prevalent heart rhythm disorder in the country.

Innovating "Treadmill Exercise Test AI-Assisted Interpretation System," CMUH(Taiwan) Timely Saves More Patients with Severe Myocardial Infarction

Retrieved on: 
화요일, 4월 2, 2024

To address this issue, China Medical University Hospital (CMUH) AI Center successfully developed the "Treadmill Exercise Test AI-Assisted Interpretation System" which was trained with nearly a thousand treadmill ECG, in patients with coronary arterystenosisover 70% shown on their coronary angiography.

Key Points: 
  • To address this issue, China Medical University Hospital (CMUH) AI Center successfully developed the "Treadmill Exercise Test AI-Assisted Interpretation System" which was trained with nearly a thousand treadmill ECG, in patients with coronary arterystenosisover 70% shown on their coronary angiography.
  • The program also utilizes ten measured features and two derived features including maximal work output and peak heart rate to determine the severity of coronary artery stenosis.
  • Generally, coronary heart disease in patients of middle or senior age is presented as angina or myocardial infarction and is one of the primary causes of sudden death."
  • Dr. Wu stated, "Coronary artery stenosis is a multi-factorial condition related to smoking, advanced age, diabetes hypertension and hyperlipidemia.

Advisory - Only use authorized nicotine pouches as directed, and do not use unauthorized nicotine pouches

Retrieved on: 
수요일, 3월 20, 2024

Consuming multiple nicotine products at the same time, including authorized nicotine replacement therapy products, or varenicline (a prescription smoking cessation drug), may increase the adverse effects of nicotine.

Key Points: 
  • Consuming multiple nicotine products at the same time, including authorized nicotine replacement therapy products, or varenicline (a prescription smoking cessation drug), may increase the adverse effects of nicotine.
  • Use authorized nicotine pouches only as directed:
    To date, Health Canada has authorized only one nicotine pouch , containing 4 mg of nicotine per dose.
  • Nicotine replacement therapies, including nicotine pouches, are not authorized for recreational use or for use by nonsmokers and people under 18 years old.
  • There are no authorized nicotine pouches in Canada that contain more than 4 mg of nicotine per dose.

Ferinject® approved by Health Canada for the treatment of iron deficiency anemia in adult and pediatric patients and iron deficiency in adult patients with heart failure

Retrieved on: 
화요일, 3월 19, 2024

Research shows that rates of iron deficiency are even higher than previously reported in Canada, with the condition particularly prevalent in women of reproductive age3 and children4.

Key Points: 
  • Research shows that rates of iron deficiency are even higher than previously reported in Canada, with the condition particularly prevalent in women of reproductive age3 and children4.
  • "The news of a new treatment option tested in clinical trials is welcomed, given that oral irons may not be able to adequately deliver the desired outcomes for Canadian patients with heart failure impacted by iron deficiency."
  • Iron deficiency affects one in every two hospitalized patients with heart failure5.
  • * The New York Heart Association Functional Classification is used by Healthcare Professionals to classify patients' heart failure based on the severity of their symptoms.

FDA Approves First Medication to Treat Severe Frostbite

Retrieved on: 
수요일, 2월 14, 2024

SILVER SPRING, Md., Feb. 14, 2024 /PRNewswire/ -- Today, the U.S. Food and Drug Administration approved Aurlumyn (iloprost) injection to treat severe frostbite in adults to reduce the risk of finger or toe amputation.

Key Points: 
  • SILVER SPRING, Md., Feb. 14, 2024 /PRNewswire/ -- Today, the U.S. Food and Drug Administration approved Aurlumyn (iloprost) injection to treat severe frostbite in adults to reduce the risk of finger or toe amputation.
  • Frostbite can occur in several stages, ranging from mild frostbite that does not require medical intervention and does not cause permanent skin damage, to severe frostbite when both the skin and underlying tissue are frozen and blood flow is stopped, sometimes requiring amputation.
  • Iloprost's efficacy in treating severe frostbite was primarily established in an open-label, controlled trial that randomized 47 adults with severe frostbite, who all received aspirin by vein and standard of care, into one of three treatment groups.
  • The two other groups received other medications that are unapproved for frostbite, given with iloprost (Group 2) or without iloprost (Group 3).

Romance isn’t always rosy, sometimes it’s sickening – lovesickness, erotomania and death by heartbreak explained

Retrieved on: 
화요일, 2월 13, 2024

All you need is love.

Key Points: 
  • All you need is love.
  • It’s better to have loved and lost than never to have loved at all.
  • But is love all pink hearts, roses and teddy bears – or is there a darker side?

Pathological Love

  • Love can hurt.
  • Ian McEwan framed a pathological form of affection, leading to obsession in his 1997 novel “Enduring Love”.
  • They appear even in the words of Hippocrates, described as a form of unrequited love.
  • The condition has seen a renaissance, over the past three centuries, shifting from unanswered love to sex addiction, to its current standing of delusions of love.

I love Paris in the springtime

  • Love, or perceptions of love for material objects or places rather than individuals might also be enough to trigger psychiatric illness.
  • Stendhal was not a psychiatrist, but a writer, who found himself overcome by the beauty of Florence when travelling there in 1817.
  • For others, unfortunately not – leading to a condition known as Paris Syndrome.

Too many broken hearts in the world

  • The term broken heart syndrome applies to a genuine cardiac condition – Takotsubo cardiomyopathy.
  • The underlying cause of broken heart syndrome?
  • The raised levels of adrenaline have been proposed as an underlying cause of broken heart syndrome – a link between heart and mind – though more research is required to tell for sure.


Dan Baumgardt does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

Human medicines European public assessment report (EPAR): Eladynos, abaloparatide, Date of authorisation: 12/12/2022, Revision: 3, Status: Authorised

Retrieved on: 
화요일, 1월 2, 2024

Human medicines European public assessment report (EPAR): Eladynos, abaloparatide, Date of authorisation: 12/12/2022, Revision: 3, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Eladynos, abaloparatide, Date of authorisation: 12/12/2022, Revision: 3, Status: Authorised

Tenaya Therapeutics Announces FDA Clearance to Begin Clinical Testing of TN-401 Gene Therapy for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy

Retrieved on: 
목요일, 10월 26, 2023

SOUTH SAN FRANCISCO, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, announced today that the U.S. Food and Drug Administration (FDA) has provided clearance of the company’s Investigational New Drug (IND) application to initiate clinical testing of TN-401.

Key Points: 
  • TN-401 is Tenaya’s adeno-associated virus serotype 9 (AAV9)-based investigational gene therapy product candidate for the treatment of arrhythmogenic right ventricular cardiomyopathy (ARVC) caused by mutations in the plakophilin-2 (PKP2) gene.
  • Tenaya is currently conducting the RIDGE™ global non-interventional natural history and serotype study of PKP2-associated ARVC.
  • ARVC, also known as arrhythmogenic cardiomyopathy (ACM), is a chronic, progressive, familial disease that typically presents before age 40.
  • People with ARVC experience symptoms related to ventricular arrhythmias, including palpitations, lightheadedness and fainting, and are at increased risk of sudden cardiac death.

Study Helps Explain How COVID-19 Heightens Risk of Heart Attack and Stroke

Retrieved on: 
목요일, 9월 28, 2023

Experts have long observed that the COVID-19 coronavirus increases the likelihood of having a heart attack or stroke for up to a year after infection, particularly for those who already have underlying heart conditions.

Key Points: 
  • Experts have long observed that the COVID-19 coronavirus increases the likelihood of having a heart attack or stroke for up to a year after infection, particularly for those who already have underlying heart conditions.
  • Notably, the researchers say, two of the identified cytokines, interleukin-1 beta and interluekin-6, have already been linked to heart attacks.
  • "These results shed light onto a possible connection between preexisting heart issues and long COVID symptoms," said study senior author and cardiologist Chiara Giannarelli, MD, PhD.
  • Further funding was provided by the American Heart Association grant 20SFRN35210252 and a Chan Zuckerberg Initiative grant.